Abstract: Liposomes of a size of less than 200 nanometers target ischemic myocardial tissue and preferentially deliver active agents to infarcted areas in the absence of antibodies bound to the liposomes to effect the delivery.

Abstract: A carboxyvinyl polymer having Newtonian viscosity, ophthalmic preparations containing the polymer, a process for preparing the polymer, and a vehicle for ophthalmic preparations containing the polymer. By using the polymer in a vehicle, an ophthalmic preparation having a low viscosity and a desirable permeability of a drug can be obtained.

Abstract: The present invention relates to cosmetic compositions containing at least one polyethoxylated vitamin E species, which may be prepared by reacting a vitamin E with ethylene oxide, and exhibit an excellent cell protecting activity in the living body. The cosmetic compositions in the form of a skin-care, hair-care, lip-care and make-up cosmetic composition, which contain at least one polyethoxylated vitamin E species in an amount of 0.01 to 50% by weight, provide a protection against harmful oxygen species, show a moisture retention ability, and increase the tensile strength of hair, and substantivity and durability of the cosmetic compositions, when applied to the skin or hair.

Abstract: A method of pulsatile infusion of a drug or other therapeutic agent is described. The pulsatile infusion method minimizes tachyphylaxis, while enabling the target cell, tissue, or organ to benefit from the administered drug or other therapeutic agent. The drug or other therapeutic agent, an agonist or antagonist for a molecule of the receptor system, is administered in a succession of at least two pulses. The pulses have a selected amplitude and duration so that the binding affinity of the receptor system molecule is decreased by a predetermined amount in response to each pulse. This predetermined amount is less than the difference between the maximum binding affinity of the receptor system molecule, when it is not exposed to either the agonist or antagonist, and its minimum binding affinity for the agonist or antagonist, when it is continuously exposed to the agonist or antagonist.

Abstract: Methodologies have been developed and certain recognizing substances and crosslinking reagents have been identified to modify liposomes. Crosslinking reagents link residues on the liposomal surface to the residues offered by certain recognizing substances. The crosslinking reagents include glutaraldehyde (GAD) and a water soluble carbodiimide, preferably, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The recognizing substances include gelatin, collagen, and hyaluronic acid (HA). Following these methodologies, recognizing substances can be utilized as an adhesive or glue to attach the liposomes onto a target area. These "bioadhesive" liposomes offer potential advantages as a microscopic drug delivery system.

Abstract: A device for the local delivery of a substance into a natural tissue conduit in the mammalian body, having a first clement capable of contacting the lumen of the conduit and a second element which overlays first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit such that a substance placed in the reservoir is delivered into the conduit. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing the device of the present invention.

Abstract: A lipid-polymer conjugate for use in forming long-circulating liposomes is disclosed. The conjugate includes a vesicle-forming lipid having covalently attached to its polar head group, one of the polymers: polyvinylpyrrolidone, polyvinylmethylether, polyhydroxypropyl methacrylate, polyhydroxypropylmethacrylamide, polyhydroxyethyl acrylate, polymethacrylamide, polydimethylacrylamide, polymethyloxazoline, polyethyloxazoline, polyhydroxyethyloxazoline, polyhydroxypropyloxazoline, or polyaspartamide. A method for preparing liposomes containing the lipid-polymer conjugate is also disclosed.

Abstract: The invention relates to microcapsules with a mixed wall of crosslinked atelocollagen and polyholosides, for example glycosaminoglycans, and to processes for the manufacture of the said microcapsules. According to the invention, the microcapsules comprise a mixed wall of crosslinked atelocollagen and polyholosides, for example glycosaminoglycans, the proportion of polyholosides, for example glycosaminoglycans, relative to the atelocollagen preferably being between 18 and 50% by weight. These microcapsules can be manufactured either by a process involving interfacial crosslinking or by the extrusion of a laminar flow which is broken up by vibrations into individual droplets, which fall into a crosslinking bath. These microcapsules are biocompatible by virtue of the presence of atelocollagen, which has most of the advantageous properties of collagen, namely a very low antigenicity and a perfect biodegradability.

Abstract: The present invention includes a process for rejuvenating a spent aqueous alkanolamine solution comprising use of alkyl-substituted ammonium-containing organic base treatment to remove inorganic ions.

Abstract: High concentrations of collagenase as active ingredient in non-aqueous topical pharmaceutical formulations.

Abstract: The invention concenrs giant ring compounds containing about 20 to about 160 atoms in the backbone of the ring and methods for preparing the giant ring compounds.

Abstract: A skin cream composition according to the present invention provides significant retexturization of the skin, producing significantly improved smoothness, as well as significantly minimizing age spots and improving color of the skin, together with increasing the firmness and moisture content of the skin. The composition can comprise: water, and emulsified and dispersed in the water: (1) sodium lactate; (2) a micellar complex comprising horse chestnut extract, Crataegus extract, water, panthenol, propylene glycol, phospholipids, phenoxyethanol, glycosphingolipids, chlorphenesin, and cholesterol; (3) a protein complex comprising serum proteins, hydrolyzed animal proteins, and glycogen; (4) a carbohydrate-based complex comprising dextran, glycine, and glucosamine; (5) a long-chain fatty acid ester of retinol; (6) a long-chain fatty acid ester of ascorbic acid; and (7) a short-chain fatty acid ester of tocopherol.

Abstract: A biocompatable multi-layer article suitable for use in blood oxygenation is disclosed. The article is made up of a microporous polypropylene tube, a perm-selective, water vapor impermeable, carbon dioxide and oxygen permeable, homogeneous layer directly adhered to the polypropylene tube and active heparin linked through a covalent bond to the permselective layer. The polypropylene tube has an inside diameter from 240 to 400 .mu.m, a wall thickness from 10 to 50 .mu.m, and a porosity from 20 to 80 percent. The perm-selective layer is a polysulfone which has the structure ##STR1## where R is an alkyl group having 16 carbon atoms and n is 3,500 to 35,000. A method for producing a biocompatible multi-layer article suitable for use in blood oxygenation is also disclosed. The method involves the steps of immersing a microporous polypropylene tube which has an inside diameter from 240 to 400 .mu.m, a wall thickness from 10 to 50 .mu.

Abstract: The present invention relates to method for preventing or treating cachexia in a mammal based on the administration of a therapeutically effective amount of an anti-cachexia agent. Suitable agents include ADP-ribose-polymerase inhibitors, ADP-ribose-transferase inhibitors, NADase inhibitors, nicotinamide benzamide, theophylline, thymine and analogs thereof.

Abstract: A process for preparing an oil-in-water emulsion of a drug which is poorly soluble in water wherein the drug (e.g. amphotericin B) is dissolved in a solution of high or low pH prior to the formation of the drug emulsion. The solution of high pH is preferably a 0.5M solution of sodium hydroxide and/or potassium hydroxide and the solution of low pH is preferably a 0.5M solution of hydrochloric acid. The process comprises the steps of (a) dissolving the drug in a solution of high or low pH, (b) adding the resulting solution to a pre-formed emulsion, (c) adding to the emulsion an amount of an acid, base or buffer appropriate to neutralise at least substantially the product of step (b), and (d) where an acid or base is added in step (c), optionally adding sufficient buffer to adjust the pH of the product of step (c) to a desired value. A drug emulsion made by the process is also provided, in which the drug is primarily associated with the oil droplets.

Abstract: Hair is conditioned by applying to the hair an effective amount of a composition which includes as the hair conditioning agent, from 0.5 to 5.0 percent by weight of a derivatized amine functional organosilicon compound which is one of (i) a reaction product of an amine functional polysiloxane and a derivative of carbonic acid; (ii) a reaction product of an amine functional polysiloxane and a lactone; (iii) a reaction product of an amine functional silane and a derivative of carbonic acid; or (iv) a reaction product of an amine functional silane and a lactone.

Abstract: A process for the preparation of microcapsules containing biologically active material is disclosed. The process involves dissolving a polymer into a solvent into which the active material is also introduced; atomizing the resulting suspension or solution and collecting the droplets in a non-solvent for the polymeric droplets containing active material, resulting in coagulation. Subsequently, the coagulated droplets are hardened in a second non-solvent.

Abstract: Pills or pellets containing genetic material and inert carrier material, characterized in that the inert carrier material forms the core of the pills or pellets, while the genetic material is distributed in a multitude around the core, adhering to that core in an adhesive layer and method for the preparation of pills or pellets containing genetic material and inert carrier material, characterized in that onto cores formed from inert carrier material a fluid adhesive containing genetic material is applied, if necessary diluted with other material, in a quantity corresponding with at least two genetic material units per present inert core, making up the adhesive layer, or that the genetic material is first mixed with a powdery adhesive, if necessary diluted with other powdery material in a quantity so that per present core at least two genetic material units are available, after which the mixture of genetic material and at least adhesive, and simultaneous addition of fluid to form the adhesive layer, is applied

Abstract: A liposome composition which comprises a substantially uniform sized inorganic core coated with an amphipathic organic compound and further coated with a second amphipathic vesicle forming lipid. Also disclosed are novel phenyl lipid compounds which serve as the amphipathic vesicle forming lipid and methods are described for delivering a drug for slow release into the blood stream, and for targeting a selected tissue or cells with the inorganic core liposome compositions.

Abstract: This invention relates to benzoporphyrin containing vesicles which are suitable for pharmaceutical application. In particular, the present invention relates to a liposomal preparation of benzoporphyrin (BPD) incorporated into vesicles comprising a liposome forming lipid such as EPC or DMPC at a drug to lipid ratio of greater than 100 .mu.g/umole lipid which will allow adequate drug dosing with relatively low lipid concentration. In an additional aspect of the present invention, sized liposomes are described which are storage stable. Certain sized BPD-containing vesicles (no greater than about 120 nm in diameter) permit sterilization by terminal filtration. Further, a lyophilized preparation of the BPD-lipid mixture can be obtained from aqueous buffer under conditions which do not result in vesicle fusion/aggregation or BPD precipitation.